Lysine-Proline-Valine (alpha-MSH fragment)
KPV is a tiny fragment of alpha-MSH. Three amino acids that kept the anti-inflammatory properties without the skin darkening or appetite changes. The mouse gut data is genuinely interesting: it hitches a ride into your gut lining through a built-in doorway (the PepT1 transporter) and dials down the inflammation switch inside your cells (NF-kB, if you want to sound smart at brunch). The problem is that the gap between mouse colitis models and your actual gut is enormous. People's experiences reflect that. More people are asking 'is this doing anything?' than saying it worked. Oral (enteric-coated) actually outperforms injections for gut issues, which is unusual for peptides.
Dose: 500mcg oral (enteric-coated capsules) or 200-500mcg SubQ | Frequency: Twice daily for oral, once daily for SubQ | Cycle: 4-8 weeks continuous, then reassess based on symptoms | Route: Oral (enteric-coated, preferred for gut) or SubQ
Reconstitution: For SubQ: 1mL bacteriostatic water per 5mg vial. Oral capsules need enteric coating. Plain oral gets destroyed by stomach acid.. Free reconstitution calculator.
Oral outperforms SubQ for gut issues based on what people actually report, which is unusual for peptides. The key is enteric coating. Without it you're wasting your money. For systemic inflammation, SubQ is the better route.
| Condition | Dose | Duration | Notes |
|---|---|---|---|
| Gut inflammation (IBS, IBD, post-antibiotic) | 500mcg oral (enteric-coated) 2x/day | 4-8 weeks, then reassess | The primary use case. In mouse studies, oral KPV rides that built-in doorway (PepT1 transporter) into your gut lining and shuts down the inflammation switch (NF-kB). Enteric coating is critical. Without it, stomach acid destroys the peptide. Oral outperforms SubQ for gut-specific issues, which is unusual. |
| Systemic inflammation | 200-500mcg SubQ daily | 4-8 weeks | For inflammation that isn't gut-specific (skin, joints, general), SubQ delivers KPV systemically. The anti-inflammatory mechanism (same inflammation switch) works the same way no matter where in your body the inflammation is. Less evidence here than the gut angle. |
| Skin inflammation (eczema, psoriasis) | 200-500mcg SubQ daily | 4-8 weeks | The parent hormone (alpha-MSH) has proven anti-inflammatory effects on skin. KPV keeps the anti-inflammatory part without triggering the skin-darkening side effect. Some people use it topically mixed into a carrier. Less data than the gut indication. |
| Stacked with BPC-157 for gut protocol | 500mcg KPV oral + 250-500mcg BPC-157 SubQ (abdomen) | 4-8 weeks | KPV handles the inflammatory signaling. BPC-157 handles tissue repair. Together they cover both sides of gut healing. Different mechanisms, same target organ. |
KPV (Lysine-Proline-Valine) is a three-amino-acid fragment of alpha-MSH (a hormone your body uses to manage inflammation. The name is longer than the peptide itself). It retains the anti-inflammatory properties of alpha-MSH without the skin-darkening or appetite effects. It works by dialing down that inflammation switch (NF-kB) inside your cells. Mouse colitis models show it enters intestinal cells through a specific transporter (PepT1) and reduces gut inflammation.
The mouse data is genuinely interesting. People's results are mixed. Reddit sentiment skews more negative than positive: worry and troubleshooting posts outnumber success stories roughly 1.5 to 1. About 30% of people report feeling nothing. No human clinical trials exist. If you try it, set a clear 4-week assessment point and don't extend indefinitely hoping for results that may not come.
For gut issues, oral (enteric-coated) is preferred. KPV enters intestinal cells through the PepT1 transporter, so direct gut exposure matters. Without enteric coating, stomach acid destroys it. For systemic inflammation (skin, joints), SubQ is the better route. This is unusual for the peptide space where injection is usually king.
Nausea (12%), headache (7%), fatigue (5%). Ironic that a gut compound causes nausea, but it passes. The real side effect is non-response: about 30% of people feel nothing. The Reddit threads are full of "is this even doing anything?" posts. That's worth knowing going in.
For SubQ: add 1mL of bacteriostatic water to a 5mg vial. That gives you 5mg per mL (5,000mcg per mL). For a 500mcg dose, draw 10 units on a U-100 insulin syringe. For oral use, you need enteric-coated capsules, not reconstituted liquid. Plain oral KPV gets destroyed by stomach acid.
Different mechanisms, same organ. KPV suppresses inflammatory signaling (NF-kB pathway). BPC-157 promotes tissue repair and new blood vessel growth. KPV is the brake on inflammation. BPC-157 is the accelerator on healing. Some protocols stack both. KPV is oral for gut. BPC-157 is SubQ or oral. BPC-157 has far more research (hundreds of studies) and broader real-world validation.
Often run with: BPC-157.
Early research. Preclinical only. Mouse colitis models show oral KPV reduces inflammation via the PepT1 transporter. No human clinical trials exist. Lots of people are using it, but Reddit sentiment actually skews negative: worry and troubleshooting posts outnumber positive reports roughly 1.5 to 1. FDA PCAC meeting was scheduled for July 2026.
Approval status: Not approved. Preclinical only.
These statements have not been evaluated by the FDA. This content is for educational purposes only. Consult a healthcare professional before starting any protocol. vialprep sells injection supplies, not compounds.